Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease

[1]  R. Petersen,et al.  Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study , 2015, Alzheimer's & Dementia.

[2]  E. Weeber,et al.  In vivo administration of granulocyte colony‐stimulating factor restores long‐term depression in hippocampal slices prepared from transgenic APP/PS1 mice , 2014, Journal of neuroscience research.

[3]  C. Teunissen,et al.  Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. , 2014, Journal of proteomics.

[4]  L. Honigberg,et al.  Identification of longitudinally dynamic biomarkers in Alzheimer’s disease cerebrospinal fluid by targeted proteomics , 2014, Molecular Neurodegeneration.

[5]  N. Tyagi,et al.  Exosomes: Mediators of Neurodegeneration, Neuroprotection and Therapeutics , 2014, Molecular Neurobiology.

[6]  F. Betsou,et al.  Creation of a federated database of blood proteins: a powerful new tool for finding and characterizing biomarkers in serum , 2014, Clinical Proteomics.

[7]  Y. Bailly,et al.  PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases , 2013, Nature Medicine.

[8]  Helena Brisby,et al.  Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma , 2013, Brain injury.

[9]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[10]  Henrik Zetterberg,et al.  Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. , 2013, Resuscitation.

[11]  C. Vedeler,et al.  Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls , 2012, Acta neurologica Scandinavica. Supplementum.

[12]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[13]  Justin Bedo,et al.  Blood-based protein biomarkers for diagnosis of Alzheimer disease. , 2012, Archives of neurology.

[14]  R. Derynck,et al.  TACE Activation by MAPK-Mediated Regulation of Cell Surface Dimerization and TIMP3 Association , 2012, Science Signaling.

[15]  T. Casoli,et al.  Early impairment of long-term depression in the perirhinal cortex of a mouse model of Alzheimer's disease. , 2012, Rejuvenation research.

[16]  D. Geschwind,et al.  Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. , 2012, Archives of neurology.

[17]  Guanghua Xiao,et al.  A Blood-Based Screening Tool for Alzheimer's Disease That Spans Serum and Plasma: Findings from TARC and ADNI , 2011, PloS one.

[18]  Sung-Cheng Huang,et al.  [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: Effects of aging, in vivo blockade, and anti-Aβ antibody treatment , 2011, Neurobiology of Disease.

[19]  D. Flood,et al.  A transgenic rat model of Alzheimer's disease with extracellular Aβ deposition , 2009, Neurobiology of Aging.

[20]  K. Suk,et al.  Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases , 2009, Brain Research.

[21]  B. Spann,et al.  Transcriptome Analysis of Synaptoneurosomes Identifies Neuroplasticity Genes Overexpressed in Incipient Alzheimer's Disease , 2009, PloS one.

[22]  J. Qi,et al.  Amyloid β‐protein fragments 25–35 and 31–35 potentiate long‐term depression in hippocampal CA1 region of rats in vivo , 2009, Synapse.

[23]  E. Ullian,et al.  Neuronal pentraxins mediate silent synapse conversion in the developing visual system , 2008, International Journal of Developmental Neuroscience.

[24]  Ottavio Arancio,et al.  A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment , 2008, Neurobiology of Disease.

[25]  Steffen B. E. Wolff,et al.  mGluR1/5-Dependent Long-Term Depression Requires the Regulated Ectodomain Cleavage of Neuronal Pentraxin NPR by TACE , 2008, Neuron.

[26]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[27]  David M Holtzman,et al.  Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease , 2007, Proteomics. Clinical applications.

[28]  D. Bennett,et al.  Paradoxical Upregulation of Glutamatergic Presynaptic Boutons during Mild Cognitive Impairment , 2007, The Journal of Neuroscience.

[29]  R. Huganir,et al.  Interaction of the N-Terminal Domain of the AMPA Receptor GluR4 Subunit with the Neuronal Pentraxin NP1 Mediates GluR4 Synaptic Recruitment , 2007, Neuron.

[30]  K. Becker,et al.  Microarray analysis of oxidative stress regulated genes in mesencephalic dopaminergic neuronal cells: Relevance to oxidative damage in Parkinson's disease , 2007, Neurochemistry International.

[31]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[32]  M. A. Abad,et al.  Neuronal Pentraxin 1 Contributes to the Neuronal Damage Evoked by Amyloid-β and Is Overexpressed in Dystrophic Neurites in Alzheimer's Brain , 2006, The Journal of Neuroscience.

[33]  D. Copenhagen,et al.  Neuronal Pentraxins Mediate Synaptic Refinement in the Developing Visual System , 2006, The Journal of Neuroscience.

[34]  G. Christensen,et al.  Regulation of neuronal type genes in congestive heart failure rats , 2006, Acta physiologica.

[35]  K. Ashe.  Mechanisms of memory loss in Aβ and tau mouse models , 2005 .

[36]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[37]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[38]  R. O’Brien,et al.  Narp and NP1 Form Heterocomplexes that Function in Developmental and Activity-Dependent Synaptic Plasticity , 2003, Neuron.

[39]  D. Selkoe.  Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[40]  Chulhun Kang,et al.  DNA array reveals altered gene expression in response to focal cerebral ischemia , 2002, Brain Research Bulletin.

[41]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[42]  M. Matzuk,et al.  Biochemical Interactions of the Neuronal Pentraxins , 2000, The Journal of Biological Chemistry.

[43]  J. Helms,et al.  Neuronal Pentraxin Receptor, a Novel Putative Integral Membrane Pentraxin That Interacts with Neuronal Pentraxin 1 and 2 and Taipoxin-associated Calcium-binding Protein 49* , 1997, The Journal of Biological Chemistry.

[44]  H. Vinters,et al.  Monoclonal antibody to the C‐terminus of β‐amyloid , 1994 .

[45]  R. Morris,et al.  Place navigation impaired in rats with hippocampal lesions , 1982, Nature.

[46]  J. Jhamandas,et al.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology. , 2013, Journal of psychiatry & neuroscience : JPN.

[47]  E. Teng,et al.  Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer’s disease and apoE TR mouse cortex , 2011, Acta Neuropathologica.

[48]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[49]  K. Ashe.  Mechanisms of memory loss in Abeta and tau mouse models. , 2005, Biochemical Society transactions.

[50]  H. Vinters,et al.  Monoclonal antibody to the C-terminus of beta-amyloid. , 1994, Neuroreport.